Correspondence 23-valent pneumococcal polysaccharide vaccine against pneumococcal pneumonia
Motoi Suzuki and colleagues1 found that 23-valent pneumococcal polysaccharide vaccine (PPV23) showed low to moderate effectiveness against vaccine serotype pneumococcal pneumonia in Japanese people aged 65 years or older treated at four community-based hospitals from September, 2011, to August, 2014. As the authors wrote, 7-valent pneumococcal conjugate vaccine (PCV7) became commercially available for Japanese children in February, 2010, and it was incorporated into the routine immunisation schedule for children in April, 2013.
The Indian patent office granted Pfizer a patent for its vaccine PCV13 (13-valent pneumococcal conjugate vaccine), sold here under the brand ‘Prevenar13’ for over 10 years.
Abstract BACKGROUND: Adult influenza and pneumococcal vaccination rates in Singapore are low, and factors influencing knowledge and attitudes of seniors towards influenza, pneumonia and their respective vaccines are not well-known. Our study aims to understand the barriers and facilitators towards getting influenza and pneumococcal vaccinations among seniors in Singapore, and subsequently inform the conduct of a relevant community-based educational intervention, as well as evaluate the intervention outcomes. METHODS: We performed a mixed methods study with two components: Firstly, formative research was condu...
Abstract Carbohydrate-based vaccines are among the safest and most effective vaccines and represent potent tools for prevention of life-threatening bacterial infectious diseases, like meningitis and pneumonia. The chemical conjugation of a weak antigen to protein as a source of T-cell epitopes generates a glycoconjugate vaccine, that results more immunogenic. Several methods have been used so far to characterize the resulting polysaccharide-protein conjugates. However, a reduced number of methodologies has been proposed for measuring the degree of saccharide conjugation at the possible protein sites. Here we show ...
Abstract Pneumococcal polysaccharide vaccine should be given to patients with diabetes at diagnosis with up to two further 5‐yearly doses. In 1465 representative community‐based Fremantle Diabetes Study Phase II participants with type 2 diabetes (mean age 66 years, 52% males), 624 (42.6%) self‐reported pneumococcal vaccination in the previous 5 years. Vaccination was significantly associated with insulin treatment and cardiovascular pharmacotherapy, suggesting that medical reviews provide the opportunity to address sub‐optimal coverage.
Conditions: Pneumococcal Pneumonia; Pneumonia, Bacterial Interventions: Biological: Bioconjugate pneumococcal vaccine; Biological: Multivalent plain polysaccharide vaccine Sponsor: LimmaTech Biologics AG Recruiting
CONCLUSION: Clones Colombia23F-ST338 and Netherlands15B-ST199 covered more serotypes than those previously found by other authors, including serotype 23A. These analyses reveal the importance of capsular switching in the spreading of successful clones among non-vaccine serotypes causing invasive pneumococcal disease. PMID: 28968016 [PubMed - in process]
We report that the assay is capable of detecting all the targeted serotypes and the CWP at 0.1ng/ml with some serotypes detected as low as 0.3 pg/ml. The analytical serotype specificity was determined as 98.4% using a panel of polysaccharide negative urine specimens spiked with non-pneumococcal bacterial antigens. We also report clinical sensitivities of 96.2% and specificities of 89.9% established using a panel of urine specimens from patients diagnosed with community acquired pneumonia or pneumococcal disease. This assay can be extended for testing other clinical samples and has the potential to greatly improve serotype-...